BRD4 and melanoma: In vemurafenib-resistant melanoma cells (A375R), ARNIPL showed significantly improved cytotoxic effects and reduced IC50 values compared with free drugs, indicating strong synergy through BRD4 degradation, c-Myc suppression, and increased apoptosis.